• by bcarlson@marketresearch.com
  • May 8 2015

Cartagenia Acquisition Demonstrates Need For Better LIS

Cartagenia Acquisition Demonstrates Need For Better LIS

Last year we suggested that a key driver of lab information systems was software upgrades due to genomic testing.   The kind of analysis being conducted  for clinical applications will require software that many players don’t have. Our report on(http://www.kaloramainformation.com/Laboratory-Information-Systems-7796512/.) Laboratory Information Systems suggested key companies in diagnostics would have to make partnerships and acquisitions.    Now this is happening. Such a trend is evident in a recent transaction.  Agilent Technologies announced the acquisition of Cartagenia, maker of Bench Lab, a platform for recording and sharing data produced by clinical genetics and molecular pathology laboratories.  

Cartagenia supplies diagnostic software, database systems, and related services to genetic labs and clinicians. The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Bench Lab NGS addresses the specific needs of genetic diagnostic labs and clinicians. October 2013, Cartagenia announced that more than 120 labs and clinics across three continents have now adopted its Bench platform genetics diagnostics solution for use in daily practice. Bench is a web-based software and database platform with features and knowledge sources that allow clinicians to analyze, interpret and manage genomic variations in routine diagnostics. October 2013, Cartagenia released a new version of its Bench Lab NGS module that is focused on increasing a lab’s efficiency through faster report generation and has added: Flexible templates that allow lab reports to automatically adapt to patient findings. The introduction of nuclear family analyses that take into account parent and sibling genotype and affected status, as well as the mode of inheritance hypotheses.

Cartagenia has offices in Leuven, Belgium, and Boston, Massachusetts, and its devices are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe.

Kalorama estimates that the  market for laboratory information management systems will reach 1.5 billion dollars in 2015, according to Kalorama Information. We think growth would be spurred on by the desire of clinical diagnostic laboratories to handle larger amounts of data from molecular testing and sequencing.